Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Continuous Antegrade Infusion Of Adriamycin As Adjuvant Therapy For Upper Tract Urothelial Malignancies.

W. See
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES To evaluate the feasibility, efficacy, and toxicity of antegrade chemotherapy delivered continuously as adjuvant treatment for patients with upper tract transitional cell carcinoma. METHODS During a 6-year interval, 12 patients with upper tract transitional cell malignancies underwent continuous antegrade intraluminal infusion chemotherapy (CAIIC) with adriamycin. After placement of percutaneous access and surgical treatment of the primary lesion, patients received 5-day cycles of CAIIC. Patients received between two and four treatment cycles at 2-week intervals. After therapy, patients with no evidence of residual disease were then monitored long-term with retrograde pyelography and upper tract cytology. RESULTS Twelve patients underwent a total of 35 5-day cycles of CAIIC. No patient experienced hematologic and/or local/regional toxicity during or after drug infusion. Three patients were treated for upper tract carcinoma in situ, and 9 patients had discrete exophytic tumors. Two patients died (treatment unrelated) before a final assessment of therapeutic outcome, leaving 10 patients available for evaluation of the therapeutic response. One patient with carcinoma in situ and 5 of 7 patients with discrete upper tract tumors remained disease free after surgery and adjuvant therapy. Both patients with discrete tumors in whom therapy failed had residual gross disease after primary surgical treatment. CONCLUSIONS CAIIC using adriamycin was well tolerated for periods of up to 5 days over multiple cycles. Early data suggest a limited efficacy in treating patients with gross residual disease. The efficacy of this approach in preventing the recurrence of upper tract disease after surgical ablation awaits further assessment.
This paper references
10.1016/S0022-5347(17)35383-1
Endourological management of upper tract urothelial tumors.
G. Gerber (1993)
Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract.
T. Takahashi (1998)
10.1097/00042307-199409000-00009
Therapy of superficial bladder cancer.
U. Nseyo (1996)
10.1097/00000421-199708000-00002
Continuous infusion, intravesical doxorubicin for the treatment of regionally advanced bladder cancer: a phase I-II trial.
W. See (1997)
10.1016/S0022-5347(01)61765-8
13-year experience with percutaneous management of upper tract transitional cell carcinoma.
P. Clark (1999)
10.1093/MILMED/151.1.386
Goodman and Gilman's the Pharmacological Basis of Therapeutics
W. Stigelman (1986)
10.1016/S0022-5347(01)64015-1
New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma.
A. Patel (1998)
Ureteroscopic management of transitional cell carcinoma of the upper urinary tract.
J. Huffman (1988)
Treatment options for upper tract transitional-cell carcinoma.
E. Seaman (1993)
10.1089/CLM.1998.16.55
Ureteroscopic laser treatment of upper urinary tract tumors.
D. Bagley (1998)
10.1016/S0090-4295(99)80005-3
Definitive tumor resection and percutaneous bacille Calmette-Guérin for management of renal pelvic transitional cell carcinoma in solitary kidneys.
S. Vasavada (1995)
10.1093/JNCI/84.7.510
Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity.
W. See (1992)
10.1016/S0022-5347(01)66330-4
Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis.
A. Patel (1996)
10.1016/S0022-5347(01)68157-6
Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma.
F. Keeley (1997)
10.1056/NEJM199203123261104
Clonal origin of bladder cancer.
D. Sidransky (1992)
10.1097/00000542-194105000-00013
The Pharmacological Basis of Therapeutics
L. Goodman (1941)
10.1016/0140-6736(93)92066-3
Metachronous multifocal development of urothelial cancers by intraluminal seeding
T. Habuchi (1993)
10.1016/S0022-5347(17)45847-2
Percutaneous management of upper tract transitional cell carcinoma.
S. Streem (1986)



This paper is referenced by
10.3892/ol.2013.1140
Androgen receptor decreases the cytotoxic effects of chemotherapeutic drugs in upper urinary tract urothelial carcinoma cells
Teng-Fu Hsieh (2013)
10.1586/era.11.193
Efficacy of instillations with chemotherapy or immunotherapy following endoscopic resection for upper tract urothelial carcinoma
Bassel G. Bachir (2012)
10.21037/TAU.2019.11.09
Future strategies to enhance kidney preservation in upper urinary tract urothelial carcinoma.
M. Metcalf (2020)
10.1242/jeb.02272
The effects of endogenous and exogenous nitric oxide on gut motility in zebrafish Danio rerio embryos and larvae
A. Holmberg (2006)
10.1016/B978-0-12-802404-1.00007-4
Percutaneous Approach of Upper Urinary Tract Tumors
Gheorghe Niţă (2016)
10.1089/end.2012.0608
Retrograde chemoinfusion of the upper tract: standardizing the delivery of topical adjuvant therapy.
M. Maurice (2013)
Oncology: prostate and renal Complementary medicine for the prevention or treatment of prostate cancer Related review: Fat reduction to prevent prostate cancer: waiting for more evidence?
Pp (2001)
10.1016/j.etp.2012.09.003
The potential use of primary human upper urinary tract urothelial cell carcinoma (UUT-UCC) cultured cells for prognostic indicators and chemosensitivity test.
Teng-Fu Hsieh (2013)
10.1007/978-1-59259-954-7_15
Percutaneous Approach to Upper Urinary Tract Tumors
I. Varkarakis (2006)
10.1016/S1040-8428(03)00079-9
Transitional cell carcinoma of the ureter and renal pelvis.
Z. Kırkalı (2003)
10.1007/978-1-84628-759-6_10
Urothelial carcinoma of the upper urinary tract
S. Gudjonsson (2009)
10.1080/17512433.2018.1461560
Intracavitary therapies for upper tract urothelial carcinoma
J. Knoedler (2018)
10.21037/TAU.2019.12.26
Outcomes of endoscopic management of upper tract urothelial carcinoma.
J. Knoedler (2020)
10.1007/978-94-017-0353-6_7
Beyond Literalism — Conceptions and Theoretical Remarks about Norms, Validity, Interpretation, Judicial Activism and Legal Certainty
J. Raitio (2003)
10.1007/978-3-319-51263-1_28
Intracavitary Topical Chemo and Immune Therapy of the Upper Tract
J. Hillelsohn (2018)
10.1016/B978-1-4160-6911-9.00053-0
Urothelial Tumors of the Upper Urinary Tract and Ureter
A. Sagalowsky (2012)
10.1007/978-1-84628-759-6_11
Urothelial Cell Carcinoma of the Upper Urinary Tract: Introduction
B. Inman (2009)
10.1007/978-3-319-51263-1_27
Analysis of Conservative Treatment of Upper Tract Urothelial Carcinoma
J. Hillelsohn (2018)
Semantic Scholar Logo Some data provided by SemanticScholar